ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.432,82
0,17%
S&P 500
5.189,93
0,04%
US Dollar vs BRL
5,0941
0,38%
Bitcoin
62.220,40
-0,18%
Brent Oil
83,565
0,84%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Chinook Therapeutics Inc (KDNY)

  7. Chinook Therapeutics Inc (KDNY) Notícias

KDNY

Chinook Therapeutics (KDNY)

Chinook Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KDNY
DataHoraFonteTítuloCódigoCompanhia
22/11/202318:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:KDNYChinook Therapeutics Inc
21/08/202314:21Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:KDNYChinook Therapeutics Inc
17/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KDNYChinook Therapeutics Inc
11/08/202318:02Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:KDNYChinook Therapeutics Inc
11/08/202317:39Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:KDNYChinook Therapeutics Inc
11/08/202317:35Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:KDNYChinook Therapeutics Inc
11/08/202317:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KDNYChinook Therapeutics Inc
11/08/202317:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KDNYChinook Therapeutics Inc
07/08/202317:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KDNYChinook Therapeutics Inc
01/08/202308:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KDNYChinook Therapeutics Inc
28/07/202309:00GlobeNewswire Inc.Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA NephropathyNASDAQ:KDNYChinook Therapeutics Inc
10/07/202317:01Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:KDNYChinook Therapeutics Inc
20/06/202310:06Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:KDNYChinook Therapeutics Inc
20/06/202310:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KDNYChinook Therapeutics Inc
17/06/202308:15GlobeNewswire Inc.Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
12/06/202317:00GlobeNewswire Inc.Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
12/06/202311:40Dow Jones NewsTrending: Novartis Buying Chinook Therapeutics for Up to $3.5 BillionNASDAQ:KDNYChinook Therapeutics Inc
12/06/202310:42Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:KDNYChinook Therapeutics Inc
12/06/202309:09Dow Jones NewsFlurry of European Companies Engaged in Acquisitions, Asset Sales Monday -- at a GlanceNASDAQ:KDNYChinook Therapeutics Inc
12/06/202302:53Dow Jones NewsNovartis to Acquire Chinook Therapeutics for Up to $3.5 BillionNASDAQ:KDNYChinook Therapeutics Inc
12/06/202302:00GlobeNewswire Inc.Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AGNASDAQ:KDNYChinook Therapeutics Inc
31/05/202320:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KDNYChinook Therapeutics Inc
16/05/202309:00GlobeNewswire Inc.Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney DiseaseNASDAQ:KDNYChinook Therapeutics Inc
09/05/202317:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KDNYChinook Therapeutics Inc
09/05/202317:00GlobeNewswire Inc.Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:KDNYChinook Therapeutics Inc
05/05/202317:05GlobeNewswire Inc.Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KDNYChinook Therapeutics Inc
05/05/202317:00GlobeNewswire Inc.Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) CongressNASDAQ:KDNYChinook Therapeutics Inc
28/04/202318:43Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:KDNYChinook Therapeutics Inc
27/04/202317:00GlobeNewswire Inc.Chinook Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:KDNYChinook Therapeutics Inc
17/04/202317:52Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:KDNYChinook Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KDNY

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PRIO3
PETRORIO ON
BOV
ETER3
ETERNIT ON
BOV
VVEO3
CM Hospitalar ON
BOV
COGN3
COGNA ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
CRFB3
CARREFOUR ON
BOV
SGPS3
SPRINGS ON
BOV
TELB4
TELEBRAS PN
BOV
BRKM5
BRASKEM PNA
BOV
OIBR3
OI ON
BOV
ENAT3
ENAUTA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados